Page 231 - Drug Class Review
P. 231
Drug Effectiveness Review Project
Alzheimer classification: Mild-Moderate
Groups similar at baseline: Yes
galantamine 24 mg placebo galantamine 32 mg 72.7 72.1 71.9 61.4 63.3 63.2 19.3 19.0 19.5 Primary Outcome Measures: ADAS-Cog; CIBIC-plus Secondary Outcome Measures: Proportion of patients with improvements from baseline on the ADAS- Cog of ≥ 0 and ≥ 4; DAD Timing of assessments: Baseline and weeks 3 (ADAS-Cog only), 12 and 24 Health Outcome Measures: ITT analysis of DAD at 6 months revealed significant benefit of GAL only at 32 mg/d; mean difference = 3.4; 95% CI: 0.1 – 6.7; P < 0.05; 24 mg/d mean difference = 2.8; P value not significant Int
• • • •
Final Report Update 1 Authors: Wilcock et al. Year: 2000 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Other germane population qualities: MMSE score • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
